Kairos Pharma (NYSEAMERICAN:KAPA) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a report released on Wednesday,Benzinga reports. D. Boral Capital currently has a $9.00 price target on the stock.

Kairos Pharma Stock Up 0.7 %

Shares of NYSEAMERICAN KAPA opened at $1.36 on Wednesday. Kairos Pharma has a 1-year low of $0.85 and a 1-year high of $4.00.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.